Luxiq (betamethasone valerate foam) is filed as Topical Corticosteroid. The sections below restate public label fields stored for this profile.
INDICATIONS AND USAGE Betamethasone valerate foam, 0.12% is a medium potency topical corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp.
CLINICAL PHARMACOLOGY Like other topical corticosteroids, betamethasone valerate foam has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A 2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A 2 . Pharmacokinetics Topical corticosteroids can be absorbed from intact healthy skin. The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle and the integrity of the epidermal barrier. Occlusion, inflammation and/or other disease processes in the skin may also increase percutaneous absorption. The use of pharmacodynamic endpoints for assessing the systemic exposure of topical corticosteroids is necessary due to the fact that circulating levels are well below the level of detection. Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. They are metabolized, primarily in the liver, and are then excreted by the kidneys. In addition, some corticosteroids and their metabolites are also excreted in the bile.
WARNING FLAMMABLE. AVOID FIRE, FLAME OR SMOKING DURING AND IMMEDIATELY FOLLOWING APPLICATION. Keep out of reach of children. Contents under pressure. Do not puncture or incinerate container. Do not expose to heat or store at temperatures above 120°F (49°C). Manufactured for: Xiromed, LLC. Florham Park, NJ 07932 Made in Spain For additional information: 844-XIROMED (844-947-6633) Or visit www.xiromed.com Revised: November 2018 PI-141-01
CONTRAINDICATIONS Betamethasone valerate foam, 0.12% is contraindicated in patients who are hypersensitive to betamethasone valerate, to other corticosteroids, or to any ingredient in this preparation.
The most frequent adverse event was burning/itching/stinging at the application site; the incidence and severity of this event were as follows: Incidence and severity of burning/itching/stinging Maximum severity Product Total incidence Mild Moderate Severe Betamethasone valerate foam, 0.12% n=63 34 (54%) 28 (44%) 5 (8%) 1 (2%) Betamethasone valerate lotion n=63 33 (52%) 26 (41%) 6 (10%) 1 (2%) Placebo Foam n=32 24 (75%) 13 (41%) 7 (22%) 4 (12%) Placebo Lotion n=30 20 (67%) 12 (40%) 5 (17%) 3 (10%) Other adverse events which were considered to be possibly, probably, or definitely related to betamethasone valerate foam, 0.12% occurred in 1 patient each; these were paresthesia, pruritus, acne, alopecia, and conjunctivitis. The following additional local adverse reactions have been reported with topical corticosteroids, and they may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximately decreasing order of occurrence: irritation; dryness; folliculitis; acneiform eruptions; hypopigmentation; perioral dermatitis; allergic contact dermatitis; secondary infection; skin atrophy; striae; and miliaria. Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria in some patients.
DOSAGE AND ADMINISTRATION Note: For proper dispensing of foam, can must be inverted. For application to the scalp invert can and dispense a small amount of betamethasone valerate foam, 0.12% onto a saucer or other cool surface. Do not dispense directly onto hands as foam will begin to melt immediately upon contact with warm skin. Pick up small amounts of foam with fingers and gently massage into affected area until foam disappears. Repeat until entire affected scalp area is treated. Apply twice daily, once in the morning and once at night. As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary. Betamethasone valerate foam, 0.12% should not be used with occlusive dressings unless directed by a physician.
According to its FDA label, Luxiq (betamethasone valerate foam) is approved for: INDICATIONS AND USAGE Betamethasone valerate foam, 0.12% is a medium potency topical corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp. For medical advice, please talk to your prescriber or pharmacist.
Luxiq (betamethasone valerate foam) belongs to the Topical Corticosteroid class of medications.
The FDA label lists Luxiq (betamethasone valerate foam) as: HOW SUPPLIED Betamethasone valerate foam, 0.12% is supplied as follows: 50 g aluminum can NDC 70700-141-19 100 g aluminum can NDC 70700-141-20 Store at controlled room temperature 68–77°F (20–25°C).; topical route. Available strengths and packaging vary by manufacturer.
Our ingest of the FDA label for Luxiq (betamethasone valerate foam) does not include a Boxed Warning at this time. See the full label on DailyMed for the current, authoritative version.
Public CMS NADAC pricing for Luxiq (betamethasone valerate foam) is in the range Retail prices vary widely by pharmacy, insurance, and location. Check with your pharmacy or use tools like GoodRx for current pricing.. Retail price varies by pharmacy, insurance, and manufacturer coupons.
The FDA Enforcement Report does not show an active/ongoing recall for Luxiq (betamethasone valerate foam) in our latest ingest. Recall data can change daily — verify at FDA.gov.
The FDA record lists the approval date for Luxiq (betamethasone valerate foam) as 2023-04-18.
The FDA label lists Xiromed, LLC. as a labeler/manufacturer of Luxiq (betamethasone valerate foam). Multiple firms may market generics of the same molecule.
The FDA label states: "Betamethasone valerate foam, 0.12% is supplied as follows: 50 g aluminum can NDC 70700-141-19 100 g aluminum can NDC 70700-141-20 Store at controlled room temperature 68–77°F (20–25°C)." Follow the packaging insert for the authoritative guidance.
Loading full data from Know Your Drugs Institute…